• Skip to main content
  • Skip to after header navigation
  • Skip to site footer
ERN: Emerging Researchers National Conference in STEM

ERN: Emerging Researchers National Conference in STEM

  • About
    • About AAAS
    • About NSF
    • About the Conference
    • Project Team
    • Advisory Board
  • Conference
  • Abstracts
    • Abstract Submission Process
    • Abstract Submission Guidelines
    • Presentation Guidelines
  • Travel Awards
  • Resources
    • Award Winners
    • Code of Conduct-AAAS Meetings
    • Code of Conduct-ERN Conference
    • Conference Agenda
    • Conference Materials
    • Conference Program Books
    • ERN Photo Galleries
    • Events | Opportunities
    • Exhibitor Info
    • HBCU-UP PI/PD Meeting
    • In the News
    • NSF Harassment Policy
    • Plenary Session Videos
    • Professional Development
    • Science Careers Handbook
    • Additional Resources
    • Archives
  • Engage
    • Webinars
    • 2023 ERN Recap Video
    • ERN 10-Year Anniversary Videos
    • Plenary Session Videos
  • Contact Us
  • Login

Inhibition of HSV-1-associated Ocular Neovascularization by Cyclin-dependent Kinase Inhibitors

Undergraduate #100
Discipline: Biological Sciences
Subcategory: Microbiology/Immunology/Virology

Usman Chaudhry - Xavier University of Louisiana
Co-Author(s): Thomas Vu, Elise I. LeMelle, Tatyana T. Santoke, Bria Carmichael, Hasahn Conway, Sydnie Turner, Briana Jarrett, Kevin Lam, Moamen Ismail, Willie Sparkman, Ashley N. Sankey, Monique N. Westley, Eric J. Fontenot, Eric Stewart, Heba A. Sarhan, Fiyinfolu T. Mustapha, Partha S, Bhattacharjee, and Harris E. McFerrin, Xavier University of Louisiana, LA Kenneth F. Swan, Cindy B. Morris, and Deborah E. Sullivan, Tulane University, LA Konstantin G. Kousoulas, Louisiana State University, LA



Herpes simplex virus type 1 (HSV-1) infects greater than 90% of humans worldwide and during ocular infection produces inflammation and angiogenesis that can lead to blindness. In the United States, HSV infection is the leading cause of infectioninduced blindness; nearly 40,000 new cases are reported and 300,000 cases are treated yearly. Cyclin-dependent kinases, mostly known for their involvement in the cell cycle and transcription, are involved in HSV transcription and replication. Cyclin-dependent kinase 9 (CDK9) and its downstream target, serine 2-phosphorylated RNA polymerase II, are essential in HSV -1 transcription and replication however, to date there is little literature on the role of CDKs in HSV infection of the eye or on the efficacy of CDK inhibitors in preventing HSV-1-associated ocular neovascularization and its consequences. We are testing the hypothesis that cyclin-dependent kinase 9 inhibitors (Flavopiridol, FP and 5,6-Dichloro- 1-β-D-ribofuranosylbenzimidazole, DRB) decrease angiogenesis and clinical pathology associated with ocular HSV-1 infection. To date, we have demonstrated that these inhibitors decrease vascular endothelial cell migration, invasion, tubule formation in vitro and angiogenic factor-induced angiogenesis in chick embryo and mouse Matrigel angiogenesis models. We have further determined that FP and DRB are non-toxic in rabbit and mouse eyes, and both drugs decrease mouse corneal neovascularization, clinical severity and neutrophil invasion due to HSV-1 infection to levels observed in mice treated with an antiherpetic control drug, trifluorothymidine. Additionally, FP and DRB also reduce HSV-1 replication in culture and in the eye.

Funder Acknowledgement(s): Support from the National Institute of Health through the National Institute of General Medical Sciences Grant 8P20GM103424 is gratefully acknowledged.

Faculty Advisor: Harris McFerrin,

Sidebar

Abstract Locators

  • Undergraduate Abstract Locator
  • Graduate Abstract Locator

This material is based upon work supported by the National Science Foundation (NSF) under Grant No. DUE-1930047. Any opinions, findings, interpretations, conclusions or recommendations expressed in this material are those of its authors and do not represent the views of the AAAS Board of Directors, the Council of AAAS, AAAS’ membership or the National Science Foundation.

AAAS

1200 New York Ave, NW
Washington,DC 20005
202-326-6400
Contact Us
About Us

  • LinkedIn
  • Facebook
  • Instagram
  • Twitter
  • YouTube

The World’s Largest General Scientific Society

Useful Links

  • Membership
  • Careers at AAAS
  • Privacy Policy
  • Terms of Use

Focus Areas

  • Science Education
  • Science Diplomacy
  • Public Engagement
  • Careers in STEM

Focus Areas

  • Shaping Science Policy
  • Advocacy for Evidence
  • R&D Budget Analysis
  • Human Rights, Ethics & Law

© 2023 American Association for the Advancement of Science